论文信息 - Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. - 字舞流文

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

H. Kantarjian | J. Cortes | F. Ravandi | E. Jabbour | S. O'brien | A. Advani | J. Jorgensen | Sa A. Wang | L. Fayad | R. Champlin | S. Faderl | P. Kebriaei | M. Rytting | M. Rios | S. York | M. Kwari | R. Tarnai | D. Thomas